Clinical and Laboratory Investigations
Mycosis fungoides in Patients under 20 Years of Age: Report of 7 Cases, Review of the Literature and Study of the Clinical CourseQuaglino P. · Zaccagna A. · Verrone A. · Dardano F. · Bernengo M.G.
Section of Dermatology, Department of Medical and Surgical Specialties, University of Turin, Italy
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: Mycosis fungoides (MF) is rare in young patients. Its clinical behavior is still uncertain, as some reports have suggested that it has a more aggressive course than does the adult-onset type. Aim: To ascertain if early-onset MF represents a heterogeneous group of cutaneous T cell lymphomas. Materials and Methods: Clinical, immunohistopathological and follow-up data of early-onset (<20 years of age) MF cases reported in the literature (n = 42) plus 7 described herein were compared with those of a cohort of adult-onset MF patients (n = 252) diagnosed at our institution since 1975. Results: The majority of the 49 early-onset MF patients had patch-plaque stage disease at diagnosis. Ten had hypopigmented lesions. The predominant phenotype was CD3+ CD4+CD7–CD8–. Seven patients had a stage progression, 6 with extracutaneous involvement. Five- and 10-year survival rates were 93 and 74%, respectively. Conclusions: No statistically significant differences were found in the disease course between early- and adult-onset MF.
- Diamandidou E, Cohen P, Kurzrock R: Mycosis fungoides and Sézary syndrome. Blood 1996;88:2385–2409.
- Weinstock MA, Horm JW: Mycosis fungoides in the United States: Increasing incidence and descriptive epidemiology. JAMA 1988;260: 42–46.
Smith NP, Samman PD: Mycosis fungoides presenting with areas of cutaneous hypopigmentation. Clin Exp Dermatol 1978;3:213– 216.
- Taniguchi S, Horio T, Komura J: Mycosis fungoides in the tumor stage treated by PUVA: A successful trial in a 12-year-old girl. Dermatologica 1980;160:409–413.
- Breathnach SM, McKee PH, Smith NP: Hypopigmented mycosis fungoides: Report of five cases with ultrastructural observations. Br J Dermatol 1982;106:643–649.
- Vignon-Pennamen MD, Wallach D, Aubinière E, Cottenot F: Mycosis fongoïde avec granulomes épithélioïdes. Ann Dermatol Vénéréol 1983;110:545–549.
- Gorg C, Gorg K, Bepler G, Adler G, Gropp C, Havemann K: Atypical mycosis fungoides with cerebral involvement. J Cancer Res Clin Oncol 1985;110:123–126.
- Misch KJ, McClennan KA, Marsden RA: Hypopigmented mycosis fungoides. Clin Exp Dermatol 1987;12:53–55.
- Koch SE, Zackheim HS, Williams LM, Fletcher V, LeBoit PE: Mycosis fungoides beginning in childhood and adolescence. J Am Acad Dermatol 1987;17:563–570.
- Barnhill RL, Braverman IM: Progression of pigmented and purpura-like eruptions to mycosis fungoides: Report of three cases. J Am Acad Dermatol 1988;19:25–31.
Finan MC, Chan WC, Safer LF, Wade TR: Hypopigmented mycosis fungoides with marked epidermotropism in a 4-year-old child. J Cutan Pathol 1989;16:302.
- Peters MS, Thibondeau SN, White JW, Winkelmann RK: Mycosis fungoides in children and adolescents. J Am Acad Dermatol 1990;22: 1011–1018.
- Fortson JS, Schroeter AL, Esterly NB: Cutaneous T-cell lymphoma. Arch Dermatol 1990; 126:1449–1453.
- Wilson AG, Cotter FE, Lowe DG, Stansfeld AG, Kirby JDT: Mycosis fungoides in childhood: An unusual presentation. J Am Acad Dermatol 1991;25:370–372.
- Burns MK, Ellis CN, Cooper KD: Mycosis fungoides-type cutaneous T-cell lymphoma arising before 30 years of age. J Am Acad Dermatol 1992;27:974–978.
- Whitmore SE, Simmons-O’Brien E, Rotter FS: Hypopigmented mycosis fungoides. Arch Dermatol 1994;130:476–480.
Vasseur E, Rybojad M, Vignon MD, Pauwells C, Morel P: Mycosis fongoïde de l’enfant: trois cas. Ann Dermatol Vénéréol 1995;122:686– 687.
El-Hoshy K, Hashimoto K: Adolescence mycosis fungoides: An unusual presentation with hypopigmentation. J Dermatol 1995;22:424– 427.
- Tay YK, Weston WL, Aeling JL: Treatment of childhood cutaneous T-cell lymphomas with alpha interferon plus PUVA. Pediatr Dermatol 1996;13:496–500.
- Zackheim HS, McCalmont TH, Deanovic FW, Odom RB: Mycosis fungoides with onset before 20 years of age: Review of 24 patients and report of a case diagnosed at age 22 months. J Am Acad Dermatol 1997;36:557–562.
- Hickham PR, McBurney EI, Fitzgerald RL: CTCL in patients under 20 years of age: A series of five cases. Pediatr Dermatol 1997;14: 93–97.
- Fivenson DP, Hanson CA, Nickoloff BJ: Localization of clonal T cells to epidermis in cutaneous T-cell lymphoma. J Am Acad Dermatol 1994;31:717–723.
- Bunn PA, Lamberg SI: Report of the Committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 1979; 63:725–728.
Hsu SM, Ra Ine L, Fanger H: Use of avidin-biotin-peroxidase complex (Abc) in immunoperoxidase techniques: A comparison between Abc and unlabelled antibody (Pap) procedures. J Histochem Cytochem 1981;75:734–738.
Novelli M, Fierro MT, Lisa F, De Matteis A, Quaglino P, Savoia P, Verrone A, Cambieri I, Bernengo MG: Skin infiltrating lymphocyte flow-cytometric immunophenotyping: Automated mechanical biopsy disaggregation and CD45 gating. J Invest Dermatol 1996;107:501.
- LeBoit PE, Abel EA, Cleary ML, Hoppe RT, Williams ML, Wood GS, Parslow TG: Clonal rearrangement of the T cell receptor beta in the circulating lymphocytes of erythrodermic follicular mucinosis. Blood 1988;71:1329–1333.
- Meister L, Duarte AM, Davis J, Perez JM, Schachner LA: Sézary syndrome in an 11-year-old girl. J Am Acad Dermatol 1993;28:93–95.
Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:475–480.
Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163– 170.
Nasu K, Said J, Vonderheid E, Olerud J, Sako D, Kadin M: Immunopathology of cutaneous T-cell lymphomas. Am J Pathol 1985;119:436– 447.
- Sterry W, Mielke V: CD4+ cutaneous T-cell lymphomas show the phenotype of helper/ inducer T-cells (CD45RA–CDw29+). J Invest Dermatol 1989;93:413–416.
- Cohen SR, Stenn KS, Bravermann IM, Beck GJ: Mycosis fungoides: Clinicopathologic relationships, survival, and therapy in 59 patients with observations on occupation as a new prognostic factor. Cancer 1980;46:2654–2666.
- Sausville EA, Eddy RN, Makuch RW, Fischmann AB, Schechter GP, Matthews M, Glatsein E, Ihde DC, Kaye F, Veach SR, Phelps R, O’Connor T, Trepel JB, Cotelingam JD, Gazdar AF, Minna JD, Bunn PA: Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Ann Intern Med 1988;109:372–382.
- Toro JR, Stoll HR Jr, Stomper PC, Oseroff AR: Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 1997;37:58–67.
- Rook AH, Vowels DR, Jaworsky C, Singh A, Lessin SR: The immunopathogenesis of cutaneous T-cell lymphoma. Arch Dermatol 1993; 129:486–489.
- Tan RS, Butterworth CM, McLaughlin H, Malka S, Samman PD: Mycosis fungoides: A disease of antigen persistence. Br J Dermatol 1974;91:607–616.
- Samman PD: Mycosis fungoides and other cutaneous reticuloses. Clin Exp Dermatol 1976; 1:197–214.
- Zucker-Franklin D, Hooper WC, Evatt BL: Human lymphotropic retroviruses associated with mycosis fungoides: Evidence that human T-cell lymphotropic virus type II (HTLV-II) as well as HTLV-I may play a role in the disease. Blood 1992;80:1537–1545.
- Lessin SR, Vowels BR, Rook AH: Retroviruses and cutaneous T-cell lymphoma. Dermatol Clin 1994;12:243–253.
- Boni R, Davis-Daneshfar A, Burg G, Fuchs D, Wood GS: No detection of HTLV-I proviral DNA in lesional skin biopsies from Swiss and German patients with cutaneous T-cell lymphoma. Br J Dermatol 1996;134:282–284.
- Bazarbachi A, Soriano V, Pawson R, Vallejo A, Moudgil T, Matutes E, Peries J, Molina A, de The H, Schultz TF, Catovsky D, Gill PS: Mycosis fungoides and Sézary syndrome are not associated with HTLV-I infection: An international study. Br J Haematol 1997;98:927–933.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.